Stock MLTX MOONLAKE IMMUNOTHERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

All News MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Market Closed - Nasdaq
Other stock markets
 01:29:52 31/05/2024 am IST 		5-day change 1st Jan Change
41.11 USD +0.07% Intraday chart for MoonLake Immunotherapeutics +2.88% -31.93%
07/05 MoonLake Immunotherapeutics Q1 Net Loss Widens MT
07/05 MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
GL
MoonLake Immunotherapeutics Q1 Net Loss Widens
MT
MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
AQ
MoonLake Immunotherapeutics, Komodo Health Team Up to Improve Inflammatory Skin, Joint Diseases Treatment
MT
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
BU
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 
AQ
Goldman Sachs Initiates MoonLake Immunotherapeutics at Neutral With $62 Price Target
MT
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup
DJ
HC Wainwright Adjusts Price Target on MoonLake Immunotherapeutics to $100 From $75, Maintains Buy Rating
MT
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
AQ
MoonLake Immunotherapeutics Announces Significant Improvements with Nanobody Sonelokimab over 24 Weeks in Active Psoriatic Arthritis
CI
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
GL
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
GL
Moonlake Immunotherapeutics to Present MIRA Trial Data of Nanobody Sonelokimab in Hidradenitis Suppurativa as A Late Breaker At the AAD Annual Meeting 2024
CI
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,803,044, According to a Recent SEC Filing
MT
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,540,710, According to a Recent SEC Filing
MT
MoonLake Immunotherapeutics Shares Decline After Posting Q4 Loss
MT
MoonLake Immunotherapeutics Reports Earnings Results for the Full Year Ended December 31, 2023
CI
MoonLake Immunotherapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MLTX Stock
  4. News MoonLake Immunotherapeutics